title: [Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results].
abstract: BACKGROUND
  Although surgical resection is the only curative strategy for pancreatic cancer, the prognosis of patients with pancreatic cancer remains poor. Recently, neoadjuvant treatment has been frequently employed as a promising treatment. Here, the mid-term results of neoadjuvant chemoradiotherapy(NACRT)using S-1, which has been performed in our hospital since 2008, are reported.
  
  
  METHODS
  Seventy-nine patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, who had been intended to undergo NACRT treatment using S-1, were enrolled. The NACRT comprised radiotherapy( 1.8 Gy×28 days)and full-dose twice-daily oral S-1 given on the same days as the radiotherapy. The results of the NACRT and pancreatectomy and the patients' prognoses were evaluated.
  
  
  RESULTS
  Fifty-five patients(69.6%)underwent pancreatectomy, with no case of mortality. The curative resection rate was 94.5%. Postoperative adjuvant chemotherapy was administered in 46 patients(83.6%). The 3-year survival rates of all 79 patients and 55 pancreatectomy patients were 40.1% and 50.4%, respectively.
  
  
  CONCLUSIONS
  NACRT using S-1 was found to be feasible, and good mid-term outcomes were obtained. However, analysis of the long-term outcomes and comparisons with other novel anti-cancer drugs are still required.
authors.affiliation: Dept. of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Homma
authors.forename: Goro
authors.initials: G
authors.lastname: Honda
authors.forename: Katsunori
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Masanao
authors.initials: M
authors.lastname: Kurata
authors.forename: Masahiko
authors.initials: M
authors.lastname: Honjo
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hirata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shinya
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D004338:Drug Combinations; D006801:Humans; D020360:Neoadjuvant Therapy; D010094:Oxonic Acid / Q000627:therapeutic use*; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000628:therapy*; D011379:Prognosis; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid